Skip to main content
Medical information Clinical review pending

Genetic Testing

Runx1 Runx1t1 Aml1 Eto T821 Qualitative

This test detects the RUNX1-RUNX1T1 fusion gene, a genetic marker associated with a specific type of acute myeloid leukemia (AML). It helps guide diagnosis and treatment decisions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Bone marrow or peripheral blood sample.
Results
Approximately 3-4 days. Confirm with the laboratory before booking.
Preparation
Confirm with the laboratory before booking. A doctor's prescription is required.
Test priceKSh 9,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Runx1 Runx1t1 Aml1 Eto T821 Qualitative test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Symptoms suggestive of leukemia (e.g., fatigue, infections, bruising)
  • ✓Diagnosis of Acute Myeloid Leukemia (AML)
  • ✓Risk stratification for AML
  • ✓Guiding treatment decisions for AML
  • ✓Family history of leukemia or related genetic conditions
02

In plain language

What this test helps you understand

Detects the RUNX1-RUNX1T1 fusion gene associated with a subtype of Acute Myeloid Leukemia (AML), aiding in diagnosis, prognosis, and treatment planning.
The Runx1 Runx1t1 Aml1 Eto T821 Qualitative test is a diagnostic tool used to identify specific genetic abnormalities linked to acute myeloid leukemia (AML). Detecting the RUNX1-RUNX1T1 fusion gene, which results from a chromosomal translocation (t(8;21)), is crucial for understanding the genetic basis of the leukemia. This information helps healthcare providers assess prognosis and tailor treatment strategies for patients.

This test specifically looks for the presence of the RUNX1-RUNX1T1 fusion gene. This genetic alteration is commonly found in a subtype of AML and plays a significant role in disease management and patient outcomes.

Patients experiencing symptoms suggestive of leukemia, such as persistent fatigue, frequent infections, or unusual bruising, may be advised to consider this test. Individuals with a family history of genetic disorders or those with specific risk factors might also benefit from this testing.

Benefits of this test include early detection of relevant genetic abnormalities, guidance for treatment planning, and support for monitoring the disease. The results also provide valuable information for genetic counseling and assessing familial risk.

Test results will indicate whether the RUNX1-RUNX1T1 fusion gene is detected. A positive result may support an AML diagnosis, while a negative result can help exclude this specific genetic alteration. Discussing the results with your doctor is essential for a complete understanding of their implications.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationConfirm with the laboratory before booking. A doctor's prescription is required.
SampleBone marrow or peripheral blood sample.
MethodologyReal Time PCR (Polymerase Chain Reaction).
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects the presence or absence of the specific RUNX1-RUNX1T1 fusion gene. It does not detect other genetic abnormalities associated with leukemia. A negative result does not rule out leukemia. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This test detects the presence of the RUNX1-RUNX1T1 fusion gene, a specific genetic marker associated with a subtype of Acute Myeloid Leukemia (AML).
Patients with symptoms suggestive of leukemia or those diagnosed with AML may need this test. Your doctor will advise if it's appropriate for you.
A sample of either bone marrow or peripheral blood is required for this test.
Results are typically available within 3-4 days, but this can vary. Confirm with the laboratory before booking.
Yes, a doctor's prescription is required to order this test.
A positive result indicates the presence of the RUNX1-RUNX1T1 fusion gene. Your doctor will interpret this result in the context of your overall health and diagnosis.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp